QIBA-2023与QIBA-2020肝脏MR弹性成像协议定量等效性验证
该回顾性研究对130例患者在同一次检查中分别采用QIBA-2020与QIBA-2023协议行肝脏MRE,结果显示两者肝硬度值高度相关(r=0.98)和一致(ICC=0.988),平均偏差仅0.07 kPa,且QIBA-2023协议图像质量更优、可测量肝实质面积更大。
要点
- QIBA-2023与QIBA-2020协议肝硬度值定量等效,支持纵向随访无缝切换。
- 两协议平均偏差0.07 kPa,95%一致性界限均在MRE可重复性阈值内。
- QIBA-2023协议伪影抑制更好,ROI及可测量肝实质面积显著增大。
核心结论
- QIBA-2023合规MRE协议与QIBA-2020协议肝硬度测量定量等效,且伪影抑制更佳、可测量肝实质范围更大。
研究设计与样本
- 回顾性研究纳入2024年连续130例患者,同一次成像会话中分别行QIBA-2020与QIBA-2023合规肝脏MRE协议检查。
- 采用Spearman相关、Bland-Altman分析和组内相关系数(ICC)比较肝硬度值,并参照QIBA可重复性指标评估测量变异性。
- 通过比较ROI大小及排除低置信度(交叉阴影)区域后的可测量肝实质面积评估图像质量。
关键影像表现/征象
- QIBA-2020协议平均肝硬度值为3.62 ± 1.81 kPa,QIBA-2023协议为3.69 ± 1.94 kPa。
- 两协议肝硬度值相关性极强(r = 0.98, p < 0.001),一致性极好(ICC = 0.988)。
- Bland-Altman分析示平均偏差仅0.07 kPa,95%一致性界限为-0.48至0.63 kPa,均在既定MRE可重复性阈值内。
- QIBA-2023协议产生的ROI及可测量肝实质面积显著更大,与伪影减少和图像质量改善一致。
诊断标准与关键数值
- 肝硬度定量等效性以Spearman相关系数r = 0.98、ICC = 0.988及Bland-Altman平均偏差0.07 kPa(95% LoA -0.48至0.63 kPa)为判定依据。
- 测量变异性与可重复性参照QIBA定义的可重复性指标评估,两协议间偏差均在阈值内。
临床应用与阅片要点
- 纵向随访肝硬度时可在QIBA-2020与QIBA-2023协议间切换而不影响定量解读。
- QIBA-2023协议可测量肝实质面积更大、伪影更少,有助于提高ROI放置的鲁棒性。
- 尽管两协议差异有统计学显著性,但绝对差值无临床意义,报告时不应视为硬度变化。
局限性
- 本研究为回顾性设计。
- 研究仅纳入单一年份连续患者,未报告多中心外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Magnetic resonance elastography (MRE) has become an essential noninvasive tool for quantitative assessment of liver stiffness and fibrosis staging, particularly in patients with steatotic liver disease. To enhance standardization and reproducibility, the Quantitative Imaging Biomarkers Alliance (QIBA) released an updated liver MRE profile in 2023, replacing the previous 2020 version. However, the quantitative continuity between these two protocol versions, particularly for longitudinal liver stiffness measurements, has not been sufficiently validated. This study aimed to evaluate the quantitative equivalence and clinical utility of a QIBA-2023-compliant MRE protocol through direct comparison with the conventional QIBA-2020-compliant protocol in the same subjects, with emphasis on longitudinal liver stiffness assessment and image quality.
METHODS: This retrospective study included 130 consecutive patients who underwent liver MRE in 2024. Each patient was examined using both the conventional QIBA-2020-compliant protocol and the updated QIBA-2023-compliant protocol during a single imaging session. Liver stiffness values were compared using Spearman correlation, Bland-Altman analysis, and intraclass correlation coefficients (ICC). Measurement variability and repeatability were evaluated with reference to QIBA-defined repeatability metrics. Image quality was evaluated by comparing region-of-interest (ROI) size and measurable liver parenchymal area excluding low-confidence (cross-hatched) regions.
RESULTS: Mean liver stiffness values were 3.62 ± 1.81 kPa for the conventional protocol and 3.69 ± 1.94 kPa for the updated protocol, with a very strong correlation (r = 0.98, p < 0.001) and excellent agreement (ICC = 0.988). Bland-Altman analysis showed a minimal mean bias of 0.07 kPa with 95% limits of agreement from - 0.48 to 0.63 kPa, which were within established MRE repeatability thresholds. Although the difference between protocols reached statistical significance, the absolute difference was not clinically meaningful. The updated protocol produced significantly larger ROIs and a greater measurable liver parenchymal area, consistent with reduced imaging artifacts and improved image quality.
CONCLUSIONS: The QIBA-2023-compliant MRE protocol demonstrates quantitative equivalence to the conventional QIBA-2020 protocol while offering improved artifact suppression and expanded measurable liver parenchyma. These findings support use of the updated protocol for reliable longitudinal liver stiffness assessment without compromising diagnostic performance.
引用
- Tokimori T, Saitoh S, Ohira S, et al. Quantitative equivalence of Quantitative Imaging Biomarkers Alliance (QIBA)-2023- and QIBA-2020-compliant MR elastography protocols for liver stiffness assessment. Abdom Radiol (NY). 2026. PMID: 41931134. doi:10.1007/s00261-026-05490-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。